Amplia's narmafotinib clinical trial in pancreatic cancer, ACCENT, is now recruiting
A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of narmafotinib in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients